 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 GLOBE NEWSWIRE -- VistaGen Therapeutics, Inc. NASDAQ: VTGN VistaGen, a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system CNS disorders, today announced the closing of its 100 million underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of 0.92 per share, par value 0.001 per share the Common Stock, and 2,000,000 shares of its Series D convertible preferred stock Series D Preferred Stock at a public offering price of 21.16 per share. All of the securities in the offering were sold by VistaGen. 